ReviewJournal of molecular neuroscience : MN2016
A Conceptualization of the Utility of Subjective Cognitive Decline in Clinical Trials of Preclinical Alzheimer's Disease.
Review in Journal of molecular neuroscience : MN, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Development and Validation of a Predictive Model for Identification of Cognitive Impairment Risk in Older Adults with Subjective Cognitive Decline：A Longitudinal Study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- A world view: Considerations of sociocultural diversity in the study of subjective cognitive decline in Alzheimer's disease and related dementias.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
- Feasibility of Internet-Based Mind-Body Training for Adults With Subjective Cognitive Decline: Protocol for a Randomized Controlled Trial.JMIR research protocols · 2026Article
- Effect of CPAP treatment on subjective cognitive decline in patients with mild obstructive sleep apnea syndrome.Sleep and biological rhythms · 2026Article
- Anticipating the Future in an Uncertain Present: How Individuals Living With Medically Unexplained Cognitive Complaints Value Biomarker-Based Prognostics.Health expectations : an international journal of public participation in health care and health policy · 2025Article
- Study Partner Report of Apathy in Older Adults is Associated with AD Biomarkers: Findings from the Harvard Aging Brain Study.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2024Article
- Tau levels are higher in objective subtle cognitive decline but not subjective memory complaint.Alzheimer's research & therapy · 2022Article
- Associations of Peripheral Neuropathy Defined by Monofilament Insensitivity with Mild Cognitive Impairment and Dementia in Older Adults.Dementia and geriatric cognitive disorders · 2022Article
- Assessing clinical progression from subjective cognitive decline to mild cognitive impairment with incomplete multi-modal neuroimages.Medical image analysis · 2022Article
- Self-reported subjective cognitive decline is associated with global cognition in a community sample of Latinos/as/x living in the United States.Journal of clinical and experimental neuropsychology · 2021Article
- The roles of study setting, response bias, and personality in subjective memory complaints of cognitively normal older adults.International psychogeriatrics · 2021Article
- Longitudinal evaluation of perceived stress and memory complaints in the Einstein Aging Study.Anxiety, stress, and coping · 2021Article
- Efficacies of Cognitive Interventions in the Elderly with Subjective Cognitive Decline: A Prospective, Three-Arm, Controlled Trial.Journal of clinical neurology (Seoul, Korea) · 2020Article
- Complexity Analysis of EEG, MEG, and fMRI in Mild Cognitive Impairment and Alzheimer's Disease: A Review.Entropy (Basel, Switzerland) · 2020Review
- An approach to classifying subjective cognitive decline in community-dwelling elders.Alzheimer's & dementia (Amsterdam, Netherlands) · 2020Article
- Cognitively normal women with Alzheimer's disease proteinopathy show relative preservation of memory but not of hippocampal volume.Alzheimer's research & therapy · 2019Article
- Using subjective cognitive decline to identify high global amyloid in community-based samples: A cross-cohort study.Alzheimer's & dementia (Amsterdam, Netherlands) · 2019Article
- Does informant-based reporting of cognitive symptoms predict amyloid positivity on positron emission tomography?Alzheimer's & dementia (Amsterdam, Netherlands) · 2019Article
- Article
- Prediction of Alzheimer's Pathological Changes in Subjective Cognitive Decline Using the Self-report Questionnaire and Neuroimaging Biomarkers.Dementia and neurocognitive disorders · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
This commentary outlines a conceptual model for subjective cognitive decline (SCD) in relation to Alzheimer's disease (AD) biomarkers in the preclinical stages of disease and a framework for effectively utilizing SCD in secondary prevention clinical trials. Mounting evidence supports the notion that SCD is sensitive to encroaching Aβ-amyloid and neurodegeneration. SCD has also been shown to provide additive information of AD-dementia risk beyond what is known about the biomarker status of the individual. Thus, we provide recommendations for the implementing SCD measurement in clinical trials. We argue that SCD can be measured at three catch points within the course of the clinical trial: firstly, at the initial recruitment and screening phase; secondly, to create more robust estimates of rates of AD-dementia progression; and finally, to measure subjective experiences of cognitive change and quality of life over the course of the trial as a proxy of clinically meaningful functional improvement. We provide recommendations of how SCD can be approached at each of these points. SCD is an important component of the preclinical AD-dementia trajectory. Future studies need to elucidate the interactive influence of Aβ-amyloid and tau on SCD from a spatiotemporal perspective. Even as this evidence accrues, it is clear that SCD can provide unique and additive information about rates of progression and subjectively experienced cognitive change within clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.